Thus, inhibition of PIAS3 may be an attractive therapeutic target in HR-positive breast cancer, but although the targeting of PIAS1 in breast cancers overexpressing PIAS1 could potentially relieve PIAS1-mediated epigenetic repression, the role of PIAS1 as a repressor of invasion must be considered. Here, PIAS3 is linked to breast cancer.